Tim Knotnerus

TLDR

Tim Knotnerus is CEO of AgomAb Therapeutics, a Ghent-based biotech developing antibody treatments for fibrosis, with $240M raised and a $100M Series C closed in 2023.

Overview

Tim has led AgomAb Therapeutics as CEO since February 2019 and joined the board in March 2021. Since joining, he has raised a total of $240M and built a broad pipeline focused on growth factor biology and fibrotic indications. Agomab is an argenx spin-off, inheriting strong scientific pedigree from one of Belgium's most important biotech companies.

He holds an executive MBA from IMD Business School, where he was named Valedictorian, and two Master's degrees from Utrecht University. His career includes VP Corporate Development at AM-Pharma, where he led a $600M option-to-buy deal with Pfizer and executed a Phase IIb trial, as well as earlier work as a Senior Associate at Aescap Venture.

Career Highlights

• CEO of Agomab since 2019, raised $240M including a $100M Series C (2023)
• Named CEO of the Year by European Lifestars; selected as Endpoints 20 under 40 and In Vivo Rising Leader
• Termeer Fellow; IMD Valedictorian
• Former VP Corporate Development at AM-Pharma; led $600M Pfizer option deal
• Former Senior Associate at Aescap Venture (European medtech VC)

Connections

Agomab is a spin-off from argenx, linking Tim closely to the Belgian biotech cluster anchored in Ghent. The company is backed by international life sciences VCs and is a reference case for Belgian biotech capital formation.